BTX - Brooklyn ImmunoTherapeutics slips ahead of corporate update

Small-cap stock Brooklyn ImmunoTherapeutics ([[BTX]] -13.8%) has shed more than a tenth of value so far. The company has scheduled a corporate update at 4:30 PM EST today.A 13G filing submitted by Brooklyn ImmunoTherapeutics yesterday indicates an ownership position of ~11.4% held by John D. Halpern Revocable Trust and Warren Street Legacy, LLC based on 41.6M shares outstanding as of March 31.After a sharp rise, Brooklyn ImmunoTherapeutics ended ~7.0% lower yesterday. The company announced the completion of $20M financing which it said would be used for the development of the mRNA gene editing and cell therapies technology.Formed as a result of its merger with NTN Buzztime, the clinical-stage biopharmaceutical company has risen ~5.0% over the past 30-day period despite strong retail investor interest.

For further details see:

Brooklyn ImmunoTherapeutics slips ahead of corporate update